ArticleCureus2025
Reversible Central Adrenal Insufficiency Without Identifiable Cause: A Diagnostic Challenge.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Reversible central adrenal insufficiency (CAI) is a rare disorder characterized by transient impairment of cortisol secretion due to reduced adrenocorticotropic hormone (ACTH) production. It is commonly associated with exogenous glucocorticoid use, acute illness, or certain medications; however, transient CAI can also occur without identifiable triggers. We report the case of a 45-year-old female patient with transient CAI in whom no systemic illness, medication exposure, or pituitary abnormality was identified. Laboratory evaluation revealed a markedly low morning cortisol level (1.3 µg/dL) and suppressed plasma ACTH (3.13 pg/mL). Pituitary magnetic resonance imaging (MRI) was unremarkable, and other pituitary hormones were within reference ranges. The patient received hydrocortisone therapy led to rapid symptomatic improvement and normalization of cortisol levels within three months, after which treatment was discontinued. Long-term follow-up showed sustained recovery of adrenal function. This case highlights the potential for transient CAI without apparent precipitating factors and emphasizes the importance of careful diagnostic evaluation and follow-up. Early recognition, appropriate treatment, and periodic reassessment are essential to guide therapy and confirm recovery. Recognizing such idiopathic presentations can help prevent misdiagnosis and unnecessary lifelong glucocorticoid therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.